BRPI0518007A - formulação terapêutica capaz de produzir uma resposta imune contra a interleucina-2 e uso da mesma - Google Patents

formulação terapêutica capaz de produzir uma resposta imune contra a interleucina-2 e uso da mesma

Info

Publication number
BRPI0518007A
BRPI0518007A BRPI0518007-4A BRPI0518007A BRPI0518007A BR PI0518007 A BRPI0518007 A BR PI0518007A BR PI0518007 A BRPI0518007 A BR PI0518007A BR PI0518007 A BRPI0518007 A BR PI0518007A
Authority
BR
Brazil
Prior art keywords
immune response
relates
present
response against
therapeutic
Prior art date
Application number
BRPI0518007-4A
Other languages
English (en)
Inventor
Casimiro Jose Enrique Monteiro
Livan Bladimir Alonso Sarduy
Rodriguez Rolando Perez
Davila Agustin Bienvenido Lage
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Publication of BRPI0518007A publication Critical patent/BRPI0518007A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

FORMULAçãO TERAPêUTICA CAPAZ DE PRODUZIR UMA RESPOSTA IMUNE CONTRA A INTERLEUCINA-2 E USO DA MESMA. A presente invenção se relaciona com formulações farmacêuticas úteis no câncer mediante o bloqueio da união da interleucina 2 (IL-2) a seu receptor. Mais particularmente a presente invenção se relaciona com formulações terapêuticas capazes de incrementar a imunogenicidade e da IL-2 por seu acoplamento à proteína transportadora P64k da Neisseria Meningitidis em adjuvante Montanide ISA 51 para a indução de autoanticorpos bloqueadores da IL-2 a seu receptor e métodos efetivos para o tratamento de tumores, incluindo o câncer de mama. Em outro aspecto a presente invenção se refere à combinação terapêutica da vacina baseada em IL-2 com outras vacinas de câncer baseadas em antígenos específicos de tumores ou fatores de crescimento tumoral, assim como medicamentos quimioterapêuticos ou radioterapia de uso convencional na prática oncológica.
BRPI0518007-4A 2004-11-16 2005-11-16 formulação terapêutica capaz de produzir uma resposta imune contra a interleucina-2 e uso da mesma BRPI0518007A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20040261A CU23297A1 (es) 2004-11-16 2004-11-16 Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer
PCT/CU2005/000009 WO2006053508A1 (es) 2004-11-16 2005-11-16 Formulaciones inmunoterapeuticas con capacidad neutralizante de la interleucina-2.

Publications (1)

Publication Number Publication Date
BRPI0518007A true BRPI0518007A (pt) 2008-10-21

Family

ID=40122436

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518007-4A BRPI0518007A (pt) 2004-11-16 2005-11-16 formulação terapêutica capaz de produzir uma resposta imune contra a interleucina-2 e uso da mesma

Country Status (25)

Country Link
US (1) US20090274647A1 (pt)
EP (2) EP2112160B1 (pt)
JP (1) JP5227028B2 (pt)
KR (1) KR101240457B1 (pt)
CN (1) CN101061136B (pt)
AR (1) AR051494A1 (pt)
AT (1) ATE525393T1 (pt)
AU (1) AU2005306186B2 (pt)
BR (1) BRPI0518007A (pt)
CA (1) CA2588573C (pt)
CR (1) CR9097A (pt)
CU (1) CU23297A1 (pt)
EA (1) EA012072B1 (pt)
GE (1) GEP20105039B (pt)
HK (1) HK1113374A1 (pt)
MA (1) MA29044B1 (pt)
MX (1) MX2007005808A (pt)
MY (1) MY162106A (pt)
PE (1) PE20061172A1 (pt)
SG (1) SG122897A1 (pt)
TN (1) TNSN07187A1 (pt)
TR (1) TR200704213T2 (pt)
TW (1) TWI433853B (pt)
WO (1) WO2006053508A1 (pt)
ZA (1) ZA200703528B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009542592A (ja) * 2006-07-06 2009-12-03 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｉｌ−２媒介性免疫応答の有効性を高める組成物および方法
US10114018B2 (en) 2014-04-22 2018-10-30 INSERM (Institut National de la Santé et de la Recherche Médicale) IL-2 peptide derivatives, and uses thereof for the diagnosis and treatment of an autoimmune disease
TW201722989A (zh) * 2015-10-23 2017-07-01 輝瑞大藥廠 抗il-2抗體及其組合物及用途
CU20210021A7 (es) * 2021-03-30 2022-11-07 Ct Inmunologia Molecular Composicones vacunales depletantes de factores de crecimiento hematopoyéticos para el tratamiento de enfermedades inflamatorias

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5939832A (ja) * 1982-08-28 1984-03-05 Ajinomoto Co Inc モノクロ−ナル抗体ならびにその製法、使用法
EP0111344A2 (en) * 1982-12-13 1984-06-20 Sloan-Kettering Institute For Cancer Research Anti-interleukin-2 monoclonal antibodies
US4569790A (en) * 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
US5643565A (en) * 1985-09-20 1997-07-01 Chiron Corporation Human IL-2 as a vaccine adjuvant
WO1991001146A1 (en) * 1989-07-14 1991-02-07 Praxis Biologics, Inc. Cytokine and hormone carriers for conjugate vaccines
HUT60768A (en) * 1990-03-16 1992-10-28 Sandoz Ag Process for producing cd25 fixing molecules
CU22302A1 (es) * 1990-09-07 1995-01-31 Cigb Secuencia nucleotidica codificante para una proteina de la membrana externa de neisseria meningitidis y uso de dicha proteina en preparados vacunales
US5830452A (en) * 1990-11-20 1998-11-03 Chiron Corporation Method for enhancing the anti-tumor therapeutic index of interleukin-2
JPH10147952A (ja) 1996-11-18 1998-06-02 Komatsu Ltd ブルドーザのドージング装置
US20040156824A1 (en) * 1996-12-23 2004-08-12 Epstein Alan L. Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof
CA2219961C (en) * 1998-01-09 2010-06-01 The University Of Southern California Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof
CU22731A1 (es) * 1998-02-05 2002-02-28 Centro Inmunologia Molecular Anticuerpo monoclonal que reconoce el oligosacárido ácido siálico n´glicolilado-galactosa-glucosa (ngcneu-gal-glu) en tumores malignos y composiciones farmacéuticas que los contienen
US6168785B1 (en) * 1998-07-16 2001-01-02 Institut Pasteur Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents
PL200919B1 (pl) * 1999-02-12 2009-02-27 Lexigen Pharm Corp Zastosowanie kompozycji czynnika hamującego angiogenezę i czynnika przeciwnowotworowego, kompozycja terapeutyczna do leczenia nowotworów i zestaw do traktowania komórki nowotworowej
AU2001259253A1 (en) * 2000-04-26 2001-11-07 National Jewish Medical And Research Center Product and process for regulation of t cell responses
CU23011A1 (es) * 2000-11-03 2004-12-17 Ct Ingenieria Genetica Biotech Método de obtención de estructuras antigénicas quemétodo de obtención de estructuras antigénicas que potencian la reactividad cruzada específica y su potencian la reactividad cruzada específica y su uso en formulaciones uso en formulaciones
CU23077A1 (es) * 2000-12-06 2005-08-17 Centro Inmunologia Molecular Composicion vacunal que contiene factor de crecimiento transformante (tgf-alfa). su uso en la terapia de enfermedades malignas
CU22979A1 (es) * 2000-12-08 2004-09-09 Centro Inmunologia Molecular Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina
CU22999A1 (es) * 2001-12-04 2004-10-12 Centro Inmunologia Molecular Método de tratamiento de enfermedades malignas e infecciosas crónicas
WO2002087304A2 (de) * 2001-04-30 2002-11-07 Frohnhofen, Wilfried Il2-peptide; von interleukin 2 abgeleitete peptide und peptid-dimere
US6906169B2 (en) * 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
ITMI20012527A1 (it) 2001-11-30 2003-05-30 Unihart Corp Proteine di fusione contenenti peptidi tlp
JP4364643B2 (ja) * 2001-11-30 2009-11-18 アメリカ合衆国 前立腺特異抗原のペプチドアゴニストおよびその使用
US20040208869A1 (en) * 2003-01-30 2004-10-21 Medimmune, Inc. Uses of anti-integrin alphanubeta3 antibody formulations
US7569215B2 (en) * 2003-07-18 2009-08-04 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides

Also Published As

Publication number Publication date
HK1113374A1 (en) 2008-10-03
EP2112160A3 (en) 2010-01-13
EA012072B1 (ru) 2009-08-28
EP2112160A2 (en) 2009-10-28
CR9097A (es) 2007-08-28
MX2007005808A (es) 2007-07-20
EP1829893B1 (en) 2011-09-21
CA2588573C (en) 2013-12-31
PE20061172A1 (es) 2006-12-16
EP1829893A1 (en) 2007-09-05
JP2008526686A (ja) 2008-07-24
JP5227028B2 (ja) 2013-07-03
CN101061136A (zh) 2007-10-24
EA200701071A1 (ru) 2007-12-28
ATE525393T1 (de) 2011-10-15
TNSN07187A1 (en) 2008-11-21
TR200704213T2 (tr) 2007-08-21
CA2588573A1 (en) 2006-05-26
EP2112160B1 (en) 2015-07-08
MY162106A (en) 2017-05-31
KR20070084025A (ko) 2007-08-24
AR051494A1 (es) 2007-01-17
TW200631591A (en) 2006-09-16
ZA200703528B (en) 2008-06-25
GEP20105039B (en) 2010-07-12
WO2006053508A1 (es) 2006-05-26
CN101061136B (zh) 2012-12-05
KR101240457B1 (ko) 2013-03-08
CU23297A1 (es) 2008-07-24
MA29044B1 (fr) 2007-11-01
TWI433853B (zh) 2014-04-11
AU2005306186A1 (en) 2006-05-26
US20090274647A1 (en) 2009-11-05
SG122897A1 (en) 2006-06-29
AU2005306186B2 (en) 2012-05-31

Similar Documents

Publication Publication Date Title
Apostolopoulos et al. Dendritic cell immunotherapy: clinical outcomes
BRPI0920791B8 (pt) Uso de peptídeo na preparação de medicamento para tratar câncer e kit
BR122019014468B8 (pt) uso de peptídeos de mhc de classe ii derivados de survivina
Wiedermann et al. Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines
Xia et al. L-BLP25 as a peptide vaccine therapy in non-small cell lung cancer: a review
BRPI0518007A (pt) formulação terapêutica capaz de produzir uma resposta imune contra a interleucina-2 e uso da mesma
US20230201322A1 (en) Immunogenic compounds for cancer therapy
US20230080443A1 (en) Immunogenic compounds for cancer therapy
US20160228524A1 (en) Autologous cancer cell vaccine
BR112014001363A2 (pt) peptídeos mphosph1 e vacinas incluindo os mesmos
Powell et al. BLP-25 liposomal vaccine: a promising potential therapy in nonsmall-cell lung cancer
Chang et al. Unique pulmonary antigen presentation may call for an alternative approach toward lung cancer immunotherapy
BRPI0806257A2 (pt) método de tratamento, e, uso de uma composição imunoterapêutica
MD3236985T3 (ro) Noi peptide și combinații de peptide pentru utilizare în imunoterapie împotriva carcinomului hepatocelular (HCC) și altor tipuri de cancere
Talebi et al. Immuno-stimulating peptide derived from HMGB1 is more effective than the N-terminal domain of Gp96 as an endogenous adjuvant for improvement of protein vaccines
UY29216A1 (es) Formulaciones inmunoterapeúticas para la inducción de autoanticuerpos bloqueadores de la unión de interleucina-2 a su receptor. su uso en el tratamiento del cáncer
Carson III et al. Current immunotherapeutic strategies in breast cancer
Kim et al. Unmet need in lung cancer: can vaccines bridge the gap?
TH83896A (th) สูตรในการสร้างภูมิคุ้มกันเพื่อก่อให้เกิดออโตแอนติบอดีที่สามารถหลีกเลี่ยงการเชื่อมต่อของอินเตอร์ลิวคิน-2 เข้ากับตัวรับของตัวเอง การใช้สูตรในการบำบัดรักษาโรคมะเร็ง
TH83896B (th) สูตรในการสร้างภูมิคุ้มกันเพื่อก่อให้เกิดออโตแอนติบอดีที่สามารถหลีกเลี่ยงการเชื่อมต่อของอินเตอร์ลิวคิน-2เข้ากับตัวรับของตัวเอง การใช้สูตรในการบำบัดรักษาโรคมะเร็ง
Yucel Part B: Immunological Therapies for Lung Cancer
ATE419003T1 (de) Mycobakterielle proteinantigene für krebstherapie und impfung

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2386 DE 27-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.